Novartis delays decision on Alcon spinoff until 2019
Novartis has announced that any potential action about Alcon turning into a stand-alone company is “not likely before the first half of 2019.” According to Reuters, Novartis' chief executive, Joe Jimenez, told reporters that what the company “would be considering right now is a separate listing,” and those shares would ...
Already an Eyewear Intelligence subscriber? Sign in here.
Subscribe today
Buying a membership today will give you:
- Unlimited access to ewintelligence.com - all insight and analysis available online
- Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Access to over 11,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Powerful search and intuitive navigation
- Organisation-wide access across offices, people and devices
To continue reading this article register now.